Navigation Links
MDS Pharma Services Wins Award for Management of Global Malaria Trial
Date:9/7/2007

KING OF PRUSSIA, PA, Sept. 7 /PRNewswire-FirstCall/ - MDS Pharma Services, a leading provider of innovative drug discovery and development solutions, has won the Good Clinical Practice Journal (GCPj) Award for the clinical research program that best promotes access to new medicines. This award is one of a series of inaugural GCPj awards introduced this year to recognize excellence in clinical research. MDS Pharma Services received this award during a ceremony in London where it was recognized for its successful management of a large-scale Phase III malaria drug trial involving more than 2,700 patients in Laos, India, Thailand, Burkina Faso, Kenya, Mozambique, Uganda, and Zambia.

The compound studied by MDS Pharma Services is relatively low-cost and has the potential to become a major breakthrough in the treatment of malaria, a deadly mosquito-borne disease prevalent in the world's poorest countries. According to the World Health Organization, malaria kills more than one million people each year and there are between 350 and 500 million clinical episodes of this disease occurring annually. This high incidence rate is fueled by malaria's growing resistance to existing drugs.

This malaria clinical trial was conducted by MDS Pharma Services on behalf of an international collaboration between Sigma-Tau, a leading pharmaceutical company based in Italy; the non-profit Medicines for Malaria Venture, which is supported by the Bill & Melinda Gates Foundation; China's Chongqing Holley pharmaceutical company; and Britain's Oxford University.

"At Sigma-Tau, we appreciate the challenges in carrying out a large global trial," said Sigma-Tau Medical Department Director Marco Corsi. "The successful completion of this trial was made possible by both the professionalism of the MDS people managing the trial and the personal commitment of all participants to improve the treatment of malaria - a neglected but deadly disease."

"We are really honoured by this recognition of MDS Pharma Services' role in the effort to find an easy-to-use, affordable and effective treatment for this devastating disease," said MDS Pharma Services President David Spaight. "Infectious diseases, such as HIV and malaria, are key pharmaceutical research areas that have the potential to benefit large numbers of patients around the world."

About MDS Pharma Services

MDS Pharma Services offers a full spectrum of resources to meet the drug discovery and development needs of the pharmaceutical and biotechnology industries. With numerous facilities strategically located around the world, we apply advanced scientific and technological expertise throughout the drug discovery and development process - from lead optimization, pre-IND research, early clinical research (bioequivalence, phases I-IIa) and bioanalysis through to global clinical development (phases IIb-IV), central lab and centralized cardiac services. For more information, visit our website at http://www.mdsps.com.

MDS Pharma Services is a business unit of MDS Inc. (TSX: MDS; NYSE: MDZ), a global life sciences company that provides market-leading products and services that our customers need for the development of drugs and diagnosis and treatment of disease. We are a leading global provider of pharmaceutical contract research, medical isotopes for molecular imaging, radiotherapeutics, and analytical instruments. MDS has more than 6,200 highly skilled people in 28 countries. Find out more at http://www.mdsinc.com or by calling 1-888-MDS-7222, 24 hours a day.


'/>"/>
SOURCE MDS Pharma Services
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. India to benefit from pharma companies move
2. South Africa Wins landmark case against pharmaceutical giants
3. Pharmaceutical giant offers AIDS related antifungal drug free to 50 countries
4. Pharmaceutical giant offers AIDS related antifungal drug free to 50 countries
5. Pharma cos must forge Strategic alliances
6. Setting up a new pharmaceutical industry in India
7. Medicis Pharmaceutical company enters pediatric market
8. Supply of Radiopharmaceuticals Hampered by Attacks
9. Pharma majors gear to supply anti-anthrax drug
10. Pharmacies in for a dose of bitter medicine
11. Andhra Pradesh to set up Pharma City
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... PA (PRWEB) , ... December 09, 2016 , ... "I ... Fla. "I used this old family recipe, which is meant to relieve gout and ... it gave me a 12-hour energy boost every time. It relieved what VA doctors ...
(Date:12/9/2016)... ... December 09, 2016 , ... The Holy ... in New York, NY, on December 3rd, to benefit Holy Name Medical Center's ... annual event, which raised over $1 million - the largest event in the ...
(Date:12/8/2016)... ... December 08, 2016 , ... The Florida Hospital ... and Hyperbaric Medical Society (UHMS), the leading authority in hyperbaric medicine. This accreditation ... a few hospitals and facilities have earned this distinction. This is the second ...
(Date:12/8/2016)... ... December 08, 2016 , ... Mirixa Corporation ... adherence, and other pharmacist-delivered patient care services, has announced the promotions of Karen ... to vice president of sales. , Litsinger joined Mirixa in 2008 after ...
(Date:12/8/2016)... ... December 08, 2016 , ... SunView ... customers and employees that are both engaging and easy to use. Coming off ... the software company revealed today its plans to roll out new AI-powered self-service ...
Breaking Medicine News(10 mins):
(Date:12/9/2016)... Fla. , Dec. 9, 2016  Harmar Mobility, LLC announced ... and a member of the Board of Directors. Photo ... ... Mr. Dawson,s ... development of organizations across a variety of industries. He brings to ...
(Date:12/9/2016)... -- Research and Markets has announced the addition of ... offering. ... global travel vaccines market to grow at a CAGR of 6.83% ... scenario and the growth prospects of the global travel vaccines market ... revenue generated from the sales of various vaccines administered to actively ...
(Date:12/8/2016)... -- IRIDEX Corporation (NASDAQ: IRIX ) today announced ... stock, $0.01 par value (the "Offering" with such shares being ... terms of the Offering will depend on market and other ... no assurance as to whether or when the Offering may ... proceeds it will receive from this offering for working capital ...
Breaking Medicine Technology: